Relmada Therapeutics (RLMD) Income from Non-Controlling Interests (2021 - 2022)
Relmada Therapeutics' (RLMD) quarterly Income from Non-Controlling Interests came in at -$39.7 million in Q1 2022, down 78.91% year-on-year from -$188.5 million in Q1 2021, and down 78.91% on a QoQ basis from -$22.2 million in Q1 2021.
Relmada Therapeutics (RLMD) Income from Non-Controlling Interests (2021 - 2022) Analysis & Trends
Relmada Therapeutics (RLMD) has 2 years of Income from Non-Controlling Interests data on file, last reported at -$39.7 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | - |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | - |
| 10 | Relmada Therapeutics | 452.47 Mn | 452.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -39.75 Mn |
| Mar 31, 2021 | -22.22 Mn |